Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis

This publication has 30 references indexed in Scilit:

• Reporting of Noninferiority and Equivalence Randomized Trials
  JAMA, 2006
• Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study
  The American Journal of Medicine, 2006
• Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
  New England Journal of Medicine, 2005
• Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
  New England Journal of Medicine, 2005
• Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
  Hypertension, 2003
• Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial
  Rheumatology, 2003
• Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program
  American Heart Journal, 2003
• Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use
  Gastroenterology, 2003
• Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
  JAMA, 2000
• The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
  Arthritis & Rheumatism, 1988